Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245130694> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4245130694 endingPage "A634" @default.
- W4245130694 startingPage "A633" @default.
- W4245130694 abstract "Mirabegron is a first-in-class beta-3 adrenoceptor agonist for the treatment of overactive bladder (OAB) that demonstrated superior efficacy compared to placebo by reducing OAB symptoms and improving HRQoL. We sought to assess the cost-effectiveness of mirabegron 50 mg in comparison with current antimuscarinics for the treatment of patients with OAB in the UK. A Markov model was developed to simulate the therapeutic management, the changes in symptoms (micturitions and incontinence), and complications in hypothetical cohorts of OAB patients. The model was used to predict costs and QALYs over 5 years in cohorts initially treated with antimuscarinics or mirabegron 50mg. Effectiveness and safety data were based on the results from a mixed treatment comparison (MTC). A calibration approach was used to derive transition probabilities from mean changes in frequency of micturitions and incontinence episodes. Other input data were obtained from several sources, including scientific literature and expert opinions. Costs were evaluated from the UK National Health Service (NHS) perspective and included costs of drug acquisition, GP visits, specialist visit, incontinence pad use and botox injections. Utilities were obtained from equations predicting EQ-5D index scores according to symptom severity, estimated from a clinical trial of Mirabegron. The Mirabegron strategy was slightly more expensive and associated with a greater number of QALYs, as a result of improved persistence, related to a lower risk of adverse event compared to each antimuscarinic. Mirabegron 50mg was found to be cost-effective compared to each antimuscarinic, with an ICER of £340 vs. solifenacin 10mg, £3,607 versus fesoterodine 4mg, £3,715 vs. tolterodine ER 4mg, £3,878 vs. oxybutynin ER 10mg, £8,881 versus trospium chloride MR 60 mg, £12,493 versus solifenacin 5mg, and £14,234 oxybutynin IR 10mg. Treatment with mirabegron appears to be a cost-effective strategy compared with antimuscarinics from a UK NHS perspective." @default.
- W4245130694 created "2022-05-12" @default.
- W4245130694 creator A5006408524 @default.
- W4245130694 creator A5024171925 @default.
- W4245130694 creator A5026814798 @default.
- W4245130694 creator A5028834947 @default.
- W4245130694 creator A5042478290 @default.
- W4245130694 creator A5064197337 @default.
- W4245130694 creator A5073241338 @default.
- W4245130694 creator A5073364023 @default.
- W4245130694 date "2013-11-01" @default.
- W4245130694 modified "2023-09-30" @default.
- W4245130694 title "Cost-Effectiveness of Mirabegron Compared with Antimuscarinics for the Treatment of Patients with Overactive Bladder in the United Kingdom" @default.
- W4245130694 doi "https://doi.org/10.1016/j.jval.2013.08.1887" @default.
- W4245130694 hasPublicationYear "2013" @default.
- W4245130694 type Work @default.
- W4245130694 citedByCount "2" @default.
- W4245130694 countsByYear W42451306942014 @default.
- W4245130694 countsByYear W42451306942023 @default.
- W4245130694 crossrefType "journal-article" @default.
- W4245130694 hasAuthorship W4245130694A5006408524 @default.
- W4245130694 hasAuthorship W4245130694A5024171925 @default.
- W4245130694 hasAuthorship W4245130694A5026814798 @default.
- W4245130694 hasAuthorship W4245130694A5028834947 @default.
- W4245130694 hasAuthorship W4245130694A5042478290 @default.
- W4245130694 hasAuthorship W4245130694A5064197337 @default.
- W4245130694 hasAuthorship W4245130694A5073241338 @default.
- W4245130694 hasAuthorship W4245130694A5073364023 @default.
- W4245130694 hasBestOaLocation W42451306941 @default.
- W4245130694 hasConcept C126322002 @default.
- W4245130694 hasConcept C126894567 @default.
- W4245130694 hasConcept C142724271 @default.
- W4245130694 hasConcept C197934379 @default.
- W4245130694 hasConcept C204787440 @default.
- W4245130694 hasConcept C27081682 @default.
- W4245130694 hasConcept C2778164427 @default.
- W4245130694 hasConcept C2778941218 @default.
- W4245130694 hasConcept C535046627 @default.
- W4245130694 hasConcept C71924100 @default.
- W4245130694 hasConceptScore W4245130694C126322002 @default.
- W4245130694 hasConceptScore W4245130694C126894567 @default.
- W4245130694 hasConceptScore W4245130694C142724271 @default.
- W4245130694 hasConceptScore W4245130694C197934379 @default.
- W4245130694 hasConceptScore W4245130694C204787440 @default.
- W4245130694 hasConceptScore W4245130694C27081682 @default.
- W4245130694 hasConceptScore W4245130694C2778164427 @default.
- W4245130694 hasConceptScore W4245130694C2778941218 @default.
- W4245130694 hasConceptScore W4245130694C535046627 @default.
- W4245130694 hasConceptScore W4245130694C71924100 @default.
- W4245130694 hasIssue "7" @default.
- W4245130694 hasLocation W42451306941 @default.
- W4245130694 hasOpenAccess W4245130694 @default.
- W4245130694 hasPrimaryLocation W42451306941 @default.
- W4245130694 hasRelatedWork W2003638941 @default.
- W4245130694 hasRelatedWork W2110991424 @default.
- W4245130694 hasRelatedWork W2156905627 @default.
- W4245130694 hasRelatedWork W2313053739 @default.
- W4245130694 hasRelatedWork W2743658275 @default.
- W4245130694 hasRelatedWork W2771609797 @default.
- W4245130694 hasRelatedWork W2784905695 @default.
- W4245130694 hasRelatedWork W2889116823 @default.
- W4245130694 hasRelatedWork W3171971260 @default.
- W4245130694 hasRelatedWork W3183154598 @default.
- W4245130694 hasVolume "16" @default.
- W4245130694 isParatext "false" @default.
- W4245130694 isRetracted "false" @default.
- W4245130694 workType "article" @default.